Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
Sponsor: Boehringer Ingelheim
Listed as NCT04360226, this observational or N/A phase trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 11 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2024 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2022 — May 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2022 — Sep 2022 [monthly]
Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Recruiting
-
Feb 2021 — Nov 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
May 2020 — Nov 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Respiratory Effectiveness Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almería, Spain , Barcelona, Spain , Granada, Spain , Hanyang, South Korea , Ljubljana, Slovenia , Sassari, Italy , Seoul, South Korea , Singapore, Singapore , Ulsan, South Korea , Valencia, Spain and 1 more location